US Patent Issued to The Feinstein Institutes For Medical Research on Dec. 16 for "Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies" (New York, New Jersey, Connecticut Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,497,446, issued on Dec. 16, was assigned to The Feinstein Institutes For Medical Research (Manhasset, N.Y.).

"Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies" was invented by Haichao Wang (Edison, N.J.), Weiqiang Chen (Garden City, N.Y.), Jian Hua Li (New York) and Kevin J. Tracey (Old Greenwich, Conn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments."

The patent was filed on Aug. 12, 2020, under Application No. 17/634,430.

*For further information, including...